The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.
Guru Murthy, Guru Subramanian and Atallah, Ehab
"Venetoclax Based Treatments As Frontline Therapy For Chronic Lymphocytic Leukemia,"
Hematology/Oncology and Stem Cell Therapy: Vol. 16
, Article 8.
Available at: https://doi.org/10.56875/2589-0646.1039
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.